FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides

US12054551B2 · kind B2 · utility

Assignee

• Sanofi · FR

Inventors

• Mark Sommerfeld · Frankfurt am Main, DE
• Thomas LANGER · Frankfurt am Main, DE
• Uwe Schwahn · Frankfurt am Main, DE
• Werner DITTRICH · Frankfurt am Main, DE
• Christine RUDOLPH · Nierstein, DE
• Matthias Dreyer · Frankfurt am Main, DE
• Soraya HÖLPER · Frankfurt am Main, DE
• Christian Lange · Frankfurt am Main, DE
• Katrin Lorenz · Frankfurt am Main, DE

Key dates

• Filing date: Jul 1, 2021
• Grant date: Aug 6, 2024
• Expiry date: Nov 19, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are FGFR1/KLB targeting agonistic antigen-binding proteins, or fragments thereof, having improved physico-chemical properties. Also provided herein are conjugates comprising an FGFR1/KLB targeting agonistic antigen-binding protein, or a fragment thereof, and at least one GLP-1R agonistic peptide. Further provided are pharmaceutical compositions comprising the antibody (or fragment thereof), or the conjugate provided herein, and the use of the antibody (or fragment thereof), or the use of the conjugate in medicine.